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Abstract 
Background: No studies have been conducted in the United Kingdom (UK) context to date 
which categorise medications in terms of appropriateness for patients with advanced dementia, 
or which examine medication use in these vulnerable patients. 
Objectives: To categorise the appropriateness of a comprehensive list of medications and 
medication classes for use in patients with advanced dementia; to examine the feasibility of 
conducting a longitudinal prospective cohort study to collect clinical and medication use data; 
and to determine the appropriateness of prescribing for nursing home residents with advanced 
dementia in Northern Ireland (NI), using the categories developed.   
Methods: Three-round Delphi consensus panel survey of expert clinicians, to categorise the 
appropriateness of medications for patients with advanced dementia (defined as having 
Functional Assessment Staging [FAST] scores ranging from 6E to 7F). This was followed by 
a  longitudinal prospective cohort feasibility study which was conducted in three nursing homes 
in NI. Clinical and medication use for participating residents with advanced dementia (FAST 
scores ranging from 6E to 7F) were collected and a short test of dementia severity administered. 
These data were collected at baseline and every three months for up to nine months or until 
death. For those residents who died during the study period, data were also collected within 14 
days of death.  The appropriateness ratings from the consensus panel survey were 
retrospectively applied to residents’ medication data at each data collection timepoint to 
determine the appropriateness of medications prescribed for these residents. 
Results:  Consensus was achieved for 87 (90%) of the 97 medications and medication classes 
included in the survey. Fifteen residents were recruited to participate in the longitudinal 
prospective cohort feasibility study, four of whom died during the data collection period. Mean 
  
numbers of medications prescribed per resident were 16.2 at baseline, 19.6 at three months, 
17.4 at six months and 16.1 at nine months respectively. Fourteen residents at baseline were 
taking at least one medication considered by the consensus panel to be never appropriate, and 
approximately 25% of medications prescribed were considered to be never appropriate. Post-
death data collection indicated a decrease in the proportion of never appropriate medications 
and an increase in the proportion of always appropriate medications for those residents who 
died.   
Conclusions: This study is the first to develop and apply medication appropriateness indicators 
for patients with advanced dementia in the UK setting.  The Delphi consensus panel survey of 
expert clinicians was a suitable method of developing such indicators. It is feasible to collect 
information on quality of life, functional performance, physical comfort, neuropsychiatric 
symptoms and cognitive function for this subpopulation of nursing home residents with 
advanced dementia. 
Key Points 
 This study is the first to develop medication appropriateness indicators forpatients 
with advanced dementia in the United Kingdom (UK) setting 
 It categorises a comprehensive list of medications and medication classes as never 
appropriate, rarely appropriate, sometimes appropriate or always appropriate for use 
in patients with advanced dementia  
 Fourteen of the fifteen participating residents at baseline were taking at least one never 
appropriate medication, and approximately 25% of medications prescribed were never 
appropriate. Post-death data collection indicated a decrease in the proportion of never 
appropriate medications and an increase in the proportion of always appropriate 
medications as death approached.   
  
 This study demonstrates the feasibility of conducting a longitudinal prospective 
cohort study to collect clinical and medication use data, and to determine the 
appropriateness of prescribing for nursing home residents with advanced dementia in 
Northern Ireland (NI) 
 
1. Introduction 
Advanced dementia is characterised by profound cognitive and functional impairment, 
inability to ambulate independently, urinary and faecal incontinence, and minimal verbal 
communication [1,2]. Studies of medication use in populations with a reduced life 
expectancy, albeit not specific to patients with advanced dementia, have highlighted the 
prevalence of suboptimal and inappropriate medication use [3-8]. Persons with advanced 
dementia are more likely to be subject to polypharmacy than healthier persons with a longer 
life expectancy and are at increased risk of inappropriate prescribing and adverse outcomes as 
a result of medication therapy [6, 9-11]. They are at greater risk of receiving overly 
aggressive care [12], and often have a prolonged terminal phase in advanced disease [13]. 
They may experience a high level of symptoms including shortness of breath, constipation, 
febrile episodes, agitation and eating problems [1, 13-19]. 
 
Medication use among patients with advanced dementia has been inadequately characterised 
to date.  Most of the limited number of studies conducted in this area [15, 20-23] have 
utilised prospective longitudinal cohort designs to describe medication use over time either as 
the key objective [15, 20, 21]  or as part of a much wider study of  end-of-life care of persons 
with advanced dementia [24], although larger cross-sectional studies of medication use which 
are less geographically limited in their study populations are starting to appear in the 
published literature [2].  Appropriateness of prescribing was considered in a number of these 
  
studies which focused on nursing home residents with advanced dementia nearing the end of 
life in the USA [2, 21, 22],  in Italian patients with advanced dementia residing in long-term 
care institutions or at home [23], and  patients admitted to an acute geriatric unit in Spain 
[25]. The majority of these studies employed the classification system developed by Holmes 
et al., [21] which categorised medications as never appropriate, rarely appropriate, 
sometimes appropriate or always appropriate for persons with advanced dementia in whom 
palliation of symptoms was the primary goal of therapy [2, 21-23].  
To the knowledge of the authors, no studies have been conducted in the United Kingdom 
(UK) context to date which categorise medication  appropriateness for patients with advanced 
dementia who are nearing the end of life or which examine medication use by these 
vulnerable patients.  The aims of this study were to develop such a classification system, to 
examine the feasibility of conducting a longitudinal prospective cohort study to collect 
clinical and medication use data, and to determine the appropriateness of prescribing for 
nursing home residents with advanced dementia in Northern Ireland (NI) using the system 
developed.  
2. Methods  
 
2.1 Delphi Consensus Panel 
Physicians who were members of the Clinical Management Group of the Northern Ireland 
Clinical Research Network for Dementia (n=9) were invited to participate in a consensus 
panel to rate medication appropriateness in persons with advanced dementia in whom 
palliation of symptoms is the primary goal of therapy. This panel is representative of 
specialists who provide care to patients with advanced dementia in the UK and includes 
geriatricians (n=4) [one of whom specialises in pharmacology and therapeutics], old age 
psychiatrists (n=4), and one neurologist.   
  
A postal questionnaire was administered in a three-round Delphi process. In the first round 
(July 2011), participants were mailed a selection of literature regarding medication use in 
palliative care, a conceptual model regarding prescribing for patients late in life (to provide 
background information and to assist in the classification of medications into appropriateness 
categories [20,21,26,27]), and a questionnaire. The questionnaire collected demographic data 
and data regarding clinical practice pertaining to each participant, including: age; sex; details 
of current job title; area of practice; and percentage of typical working week spent in clinical 
practice. Participants were also asked to indicate their professional and personal experience in 
caring for persons with dementia nearing the end of life, using a scale from 1 (representing 
limited experience) to 10 (extremely experienced). Participants were asked if they had 
received training in palliative care, and if so, whether this was delivered as part of a formal 
palliative care training programme. Participants were then asked to place the appropriateness 
of 85 medications and medication classes, into one of four categories: never appropriate, 
rarely appropriate, sometimes appropriate or always appropriate for use in patients with 
advanced dementia. Medications were selected based on the classification system used in the 
British National Formulary (BNF) [28], ensuring a rational organisation of medications into 
therapeutic classes. Participants were also given the opportunity to add any medications not 
included that they thought were important.  Physicians were instructed to assume that the 
patients for whom they were assessing medication appropriateness had Functional 
Assessment Staging (FAST) scores ranging between 6E and 7F [29, 30]. This corresponds to 
patients who need assistance with bathing, dressing and toileting, and who have urinary and 
faecal incontinence (FAST 6E); who have minimal verbal ability (FAST 7A and 7B); who 
are unable to ambulate (FAST 7C); sit up (FAST 7D); or smile (FAST 7E); or who cannot 
hold their head up (FAST 7F). While patients with FAST scores of 6E may be considered to 
have moderately-severe dementia, categorisation of the appropriateness of medications by the 
  
Delphi consenus panel included these patients to enable comparisons to be drawn with the 
system developed by Holmes et al. [21], which included patients with FAST scores of 6E and 
above.  
In the second and third rounds of the survey (January and July 2012 respectively), 
participants were mailed further copies of the questionnaire which had been modified to 
remind them of their responses in the previous round and which contained an anonymous 
summary of all responses including the most common response regarding  appropriateness of 
each medication or medication class. Consistent with other Delphi methods and other studies 
[21, 31], consensus for a medication or medication class was defined according to agreement 
on categorisation by at least 55% of the respondents (corresponding to 5 of the 9 physicians 
on the panel). This provided the opportunity to revise the medication appropriateness 
categorisations on the basis of the group's responses and aimed to increase consensus within 
each round.  Any medication(s) for which consensus was achieved by 100% of the 
respondents in a previous round was omitted from the questionnaire in the subsequent round. 
Each respondent was reimbursed £250 for their participation on completion of the three 
rounds of the survey. All responses to the final round were returned by January 2013. 
2.2 Longitudinal prospective cohort study 
2.2.1 Nursing home recruitment 
The feasibility study was conducted in three nursing homes in NI.  Nursing homes with more 
than 30 resident beds (the average number of beds in a nursing home in NI) were eligible to 
participate; this included homes for general nursing category residents and those which 
provided specialised dementia care (n=181).  Based on the authors’ knowledge of, and previous 
collaborative research programmes involving nursing homes in NI, a convenience sample of 
three homes was selected.   Written consent was obtained from the managers of these 
  
participating nursing homes. It was estimated that around one-third of residents would have 
advanced dementia (n=10 per home) and of these, 50% would participate (n=5 per home), 
yielding a total sample size of 15 residents from three nursing homes, which was considered 
sufficient for this feasibility study.   
 
2.2.2 Resident recruitment 
The recruitment process for eligible residents involved a number of stages. Nursing home 
managers identified residents with dementia and the members of nursing staff who provided 
most care to each of these residents on a regular basis (the residents’ named nurse).  Eligibility 
criteria for residents were as follows: (1) 60 years of age or older, (2) diagnosis of dementia, 
(3) FAST score between 6E and 7F, (4) resident in the nursing home for at least 30 days, (5) 
not participating in any other research or studies.  Eligibility criteria for named nurses were 
that the nurse was (1) regularly assigned to care for this resident and (2) not participating in 
any other research or studies. As residents with advanced dementia lack decisional capacity, 
written informed assent from their next-of-kin or legal guardian was obtained to screen the 
resident for eligibility to participate and to examine medical records held by residents’ primary 
care physicians (general practitioners [GPs]) to confirm a diagnosis of dementia.  Written 
informed consent was also obtained from residents’ named nurses to complete functional 
assessment staging of the resident using the FAST scale [29]. Upon confirmation of eligibility 
to participate, written assent was obtained from the residents’ next-of-kin or legal guardians 
and written informed consent obtained from residents’ named nurses for participation in the 
study.  Where more than five residents were eligible for screening at each of the three homes 
and subsequently determined to be eligible, five were randomly selected to take part in the 
study. 
 
  
2.2.3 Data Collection and Analysis 
The following data were collected at baseline: nursing home characteristics, including: 
ownership (private, statutory, voluntary, single home ownership, part of a chain of homes); 
number of nurses on staff; number of beds; type of care home (general nursing home, home 
offering specialised dementia care); location (rural or urban); number of general practices and 
GPs providing care to the nursing home; and extent of involvement of old age psychiatry in the 
home. Other data were collected at baseline and every three months for up to nine months or 
until deathbetween October 2011 and September 2012, as detailed in Table 1.  
As the Delphi consensus panel survey was completed in January 2013, the appropriateness 
ratings from the consensus panel recommendations were applied retrospectively to each 
resident’s medication data at each data collection timepoint to determine which of the residents’ 
medications were never appropriate, rarely appropriate, sometimes appropriate or always 
appropriate. The feasibility of using the proposed approach to collect clinical data and data 
pertaining to medication use was also determined. Statistical analysis was descriptive.  
2.3 Ethical and Governance Approvals 
Ethical approval was obtained from the Office for Research Ethics Committees Northern 
Ireland (ORECNI). Research governance approval was obtained from the organisations 
employing the physicians who participated in the consensus panel survey. 
3. Results 
3.1 Delphi Consensus Panel survey 
All nine physicians (7 males and 2 females, mean age 45 years) from the Clinical Management 
Group of the Northern Ireland Clinical Research Network for Dementia agreed to participate 
in the consensus panel and completed the three rounds of the survey.  Respondents spent an 
  
average of 86.6% of their working week in clinical practice and the majority (n=7) had received 
training in the delivery of palliative care; however this was not always delivered as part of a 
formal training programme.  All physicians, apart from one, rated themselves as highly 
experienced as a professional caring for persons nearing the end of life, with scores ranging 
from 4-10 (mean score for all participants = 8.33). Two physicians rated themselves as highly 
experienced in their personal lives in caring for persons with dementia nearing the end of life, 
with scores ranging from 1 – 10 (mean score for all participants = 6.43) .  
 
Increasing consensus regarding the appropriateness of medications and medication classes was 
achieved with each survey round.  Twelve medications or medication classes not included in 
rounds 1 and 2 of the survey were considered important by the physicians and subsequently 
added. After round 3, consensus had been achieved for 87 (90%) of the 97 medications and 
medication classes included in the survey.  The complete list of medications and their 
appropriateness ratings as determined by the consensus panel are detailed in Table 2. 
 
3.2 Longitudinal prospective cohort study 
3.2.1 Nursing home characteristics 
The three participating homes were privately owned with 40, 56, and 49 beds respectively 
(average number of beds = 48).  Only one home (NH 3) had an Elderly Mental Infirm (EMI) 
unit which provided specialist dementia care (n = 9 beds).  There was involvement of an old 
age psychiatry team at all three homes (psychiatrists assessed and reviewed residents with 
dementia when required) and on average, GPs from seven general practices provided care at 
each home (Table 3). 
 
3.2.2 Resident characteristics 
  
Three of the thirty-three eligible residents died before screening could take place and a number 
of next-of-kin did not return signed assent forms to allow screening to take place.  Nine 
residents per home were screened for eligibility to participate and five residents were randomly 
selected.  
 
Of the 15 residents recruited (average age 86 years), 10 were female and five were male. Prior 
to nursing home admission, eight residents resided in their own home, two in a residential 
home, one in sheltered accommodation and one in another nursing home.  The types of 
dementia documented (primarily from GP records) varied: six residents were diagnosed as 
having Alzheimer’s disease, four were coded as having vascular dementia and two had multiple 
infarct dementia.  Senile dementia was coded for two residents and one resident was diagnosed 
as having unspecified  dementia.  Mean duration of dementia was just under six years (71.4 
months).  Unadjusted Charlson co-morbidity scores ranged from 1 to 4, and age-adjusted scores 
ranged from 4 to 8.  Four residents died during the study period (three before the three-month 
data collection point and one before the six-month data collection point); documented causes 
of death were bronchial pneumonia (n=3), and a perforated bowel (n=1). One resident was 
transferred to another nursing home. 
 
FAST scores ranged from 6E (faecal incontinence) to 7D (could not sit up) at the four data 
collection points (Table 4).  NPI-NH scores are also detailed at each data collection point in 
Table 4; the presence of behavioural disturbances varied greatly across the 15 residents 
recruited to the study with each resident experiencing at least one of the 10 behavioural 
disturbances occurring in dementia throughout the duration of the study.  Caregiver distress 
scores, scores for cognitive function (using the short version of the Severe Impairment Battery 
[SIB-S]), quality of life (using the Quality of Life in late stage Dementia [QUALID] scale) and 
  
symptom management at the end of life (using the Symptom Management at the End of Life 
in Dementia [SM-EOLD] scale) are outlined in Table 4.  
 
3.2.3 Prevalence and Appropriateness of Medication Use 
Mean numbers of medications prescribed per resident were 16.2 at baseline, 19.6 at three 
months, 17.4 at six months and 16.1 at nine months respectively. This included regular and 
when-required medications, topical and ophthalmic preparations and nutritional supplements.   
 
The numbers of medications prescribed in each appropriateness category are summarised in 
Table 5. At baseline, approximately one-quarter of the medications prescribed for residents 
were considered by the consensus panel to be never appropriate. Fourteen of the 15 
participating residents were prescribed at least one of these medications. Use of medications 
classified as never appropriate by the consensus panel did not change significantly as the study 
progressed.  Similarly the percentage of medications classified as always appropriate remained 
stable over the period of data collection, ranging from 16.9% at baseline to 15.1%, 18.1% and 
18.4% at three, six and nine months respectively. The post-death data collection indicated that 
there was a decrease in the proportion of never appropriate medications (12.0%) and an 
increase in the proportion of always appropriate medications (28.0%) for those residents who 
died during the study period. 
 
4. Discussion 
 
This study utilised Delphi methodology to develop a classification system for the 
appropriateness of prescribing for patients with advanced dementia nearing the end of life.  
This method was selected as it involves sequential anonymous postal questionnaires 
  
interspersed by controlled feedback, and seeks to gain the most reliable consensus of opinion 
of a group of experts [39]. Furthermore, the avoidance of face-to-face interaction between 
group members prevents bias as each panel member is able to express their own opinions away 
from peer pressure [40].  
Categorisation of medication appropriateness showed similarities to the classification system 
developed by Holmes et al. [21], in which consensus was achieved for 69 (85%) of the 81 
included medications and medication classes. In the present study, consensus was achieved for 
a similar proportion of medications and medication classes (90%) despite the slightly higher 
number of medications and medication classes included (n = 97). There were, however, some 
notable differences; in the classification system developed by Holmes et al. [21], no consensus 
was achieved for aspirin, iron, vitamins, mineral supplements or finasteride, while in the 
present study, these medications were classified as never appropriate. Holmes et al. [21] 
classified acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists 
(memantine) as never appropriate; the consensus among the physicians in the present study 
was that these agents were rarely appropriate and sometimes appropriate respectively. 
Furthermore, there were some medications, namely expectorants and tricyclic antidepressants, 
for which classifications of appropriateness varied widely. This variation may in part be 
explained by cross-national or cultural differences in prescribing in US and UK jurisdictions 
but may also reflect the complexity and variability in decision-making regarding medication 
use at the end of life for patients with advanced dementia and the lack of evidence-based 
guidance available to guide clinical practice [8, 27, 41]. 
FAST scores for participating residents ranged from 6E to 7D during the data collection period.  
Residents with FAST scores of 6E (n=4) were in the less advanced stages of the disease, had 
higher scores on the SIB-S and better quality of life than residents with FAST scores of 7A and 
above. In the Delphi consensus process, physicians categorised the appropriateness of 
  
medications for use in patients with advanced dementia with FAST scores ranging between 6E 
and 7F. A recent study by Toscani et al. [23] examined the appropriateness of prescribing for 
Italian patients with advanced dementia residing in long-term care institutions and at home 
using the classification system developed by Holmes et al. [21]. In this study, patients with a 
FAST score of ≥ 7 were enrolled, but the authors reported data on patients with FAST scores 
of ≥ 7C as they argued that these patients had advanced dementia for which palliative care was 
clearly appropriate.  However, the classification system developed by Holmes et al. [21] 
determined medication appropriateness in the context of providing care to patients with 
moderate to severe dementia approximating FAST stages 6E, 7A, 7B and 7C, and the authors 
recognised that the criteria on appropriateness of some medications may require 
reconsideration in the view of the advanced stage of dementia among the participants [23]. In 
terms of the eligibility criteria for a subsequent extension of the present feasibility study to a 
larger study, inclusion of patients with FAST scores of 7A and above should be considered, 
although this may require the validation of the Delphi consensus panel recommendations for 
such patients and may have an impact on the number of eligible residents from which to recruit.  
Other researchers have utilised a Global Deterioration Scale (GDS) of 7 (characterised by 
profound memory deficits, minimal or no verbal communication, urinary and faecal 
incontinence and inability to walk) to define advanced dementia [1, 24]. A recent study by 
Molist Brunet et al. [25] used a combination of three measures to identify patients with 
advanced dementia: an inability to complete activities of daily living (defined by a Barthel 
index ≤ 30/100), incontinence, and difficulty recognising family members [defined as a GDS 
of ≥ 6 in the case of Alzheimer type dementia]), while Tjia et al. [2] used a Cognitive 
Performance Score (CPS) of 5 or 6 and the Minimum Data Set diagnosis of dementia [2]. There 
is a recognition in the literature that the criteria used to define advanced dementia vary between 
studies, and that a consistent definition that can be applied both in clinical practice and in 
  
research, and in a standardised manner, is required [42].  This should be considered in the 
design of any future study in nursing homes in the NI or UK contexts.  
It is well-acknowledged that dementia is associated with chronic comorbidities [23, 42, 43], 
and the findings from the present study, in which age-adjusted Charlson co-morbidity scores 
ranged from 4 to 8, corroborate this.  Although numbers recruited to this feasibility study were 
small, it has highlighted the number of patients with lack of specificity in their diagnosis of 
dementia; this is recognised to be an issue particularly because treatment and prognosis may 
differ substantially based on the differential diagnosis [44]. 
The mean numbers of medications prescribed per resident at each data collection point were 
similar to the mean number of medications prescribed per resident in the Care of Nursing Home 
Residents with Advanced Dementia [CareAD] study [20], in which patients were prescribed a 
mean of 14.6 medications. Other studies have reported lower numbers of medications per 
resident ranging from a median of 4 medications [23] to means of 5.9, 6.5 and 7.3 medications 
per person [21, 22, 25]. However, this may in part be explained by the differences in 
medications included in and excluded from the analysis in each study.  
Examination of the appropriateness of prescribing for residents using the Delphi consensus 
panel ratings revealed that 14 of the 15 residents at baseline were taking at least one medication 
considered by the consensus panel to be never appropriate, and that a significant proportion of 
medications (approximately one-quarter) prescribed were considered to be never appropriate. 
These figures are higher than those reported in previous studies [2, 21-23], but do provide 
further evidence to support the conclusions of Tjia et al. in their recent publication [2] that 
“most nursing home residents with advanced dementia receive medications of questionable 
benefit”. Variations in the prevalence reported in these studies may be explained by the 
differences in medications included in and excluded from the analysis in each study; for 
  
example, in the study by Tjia et al. [22], drugs prescribed on a when-required basis, topical 
preparations, vitamins (with the exception of vitamin D) and antimicrobials were not included 
whereas in the present study, regular and when-required medications, antimicrobials, topical 
and ophthalmic preparations and nutritional supplements were included. Further, in the 
classification system developed by Holmes et al. [21] and utilised in the studies by Tjia et al. 
[2,22] and Toscani et al. [23], no consensus was achieved for aspirin, iron, vitamins, mineral 
supplements or finasteride, while in the present study these medications were classified as 
never appropriate.  
Prescribing of medications classified as never appropriate did not change significantly as the 
study progressed.  Similarly the percentage of medications classified as always appropriate 
remained stable over the period of data collection. The post-death data collection indicated that 
there was a decrease in the proportion of never appropriate medications and an increase in the 
proportion of always appropriate medications for those residents who died during the study 
period. This is noteworthy despite the small number of residents involved; it may suggest a 
move away from curative goals of therapy towards palliative management of symptoms, as has 
been observed in other studies [3, 20, 21, 45]. 
This study is the first to develop indicators for, and to report prevalence of, appropriate 
medication use in patients with advanced dementia nearing the end of life in the UK setting. 
There are, however, some limitations to this study which must be acknowledged. The Delphi 
consensus panel took significantly longer to complete than had been originally anticipated. 
This may have been due in part to the length of the survey, which required classification of 97 
medications/medication classes into appropriateness categories. In order to facilitate the 
completion of any further consensus panel survey in an expeditious manner, administration via 
other methods such as a face-to-face meeting or online distribution could be considered.  
Furthermore, a larger representative consensus panel comprising physicians from a range of 
  
locations, clinical specialities and settings is required to extend the generalizability and scope 
of these findings. Numbers recruited to this feasibility study were small, and the ability to draw 
generalizable conclusions is limited.  Although a number of residents with FAST scores of 
between 7B-7E (severely demented) were unable to complete the short version of the SIB-S, 
use of this scale enabled assessment of cognitive function in residents who had such advanced 
dementia that they would have been unable to complete any other test of cognitive function. 
Future larger-scale studies should therefore continue to utilise the SIB-S to measure cognitive 
function. Previous work undertaken by Garfinkel et al., [46, 47] has reported that medication 
discontinuation using a geriatric-palliative approach and algorithm has favourable effects on 
mortality and morbidity, and lends support to further work developing and evaluating measures 
of medication appropriateness for older people with advanced dementia to provide an evidence-
base for rationalisation of prescribing in this vulnerable patient group. 
Despite these limitations, the Delphi consensus panel survey was a suitable method of gaining 
consensus among expert clinicians on appropriateness of medications. The study findings 
demonstrate the feasibility of collecting information from medical records, from researcher-
conducted interviews with residents’ named nurses and from a researcher assessment of 
cognitive function using the SIB-S. This three-staged approach to data collection would 
therefore be suitable for use in a larger study. 
5. Conclusion 
This study is the first to develop and apply indicators for medication appropriateness for 
patients with advanced dementia nearing the end of life in the UK setting. It demonstrates the 
feasibility and suitability of utilising a Delphi consensus panel of experts to classify the 
appropriateness of medications for use in patients with advanced dementia. Data collection 
indicated that it is feasible to collect information on quality of life, functional performance, 
  
physical comfort, neuropsychiatric symptoms and cognitive function for nursing home 
residents with advanced dementia who are nearing the end of life. 
 
6. References 
1. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J 
Med 2009;361(16): 1529-38. 
2. Tjia J, Briesacher BA, Peterson D, et al. Use of medications of questionable benefit in 
advanced dementia. JAMA Intern Med 2014 (epub ahead of print). 
3. Currow DCB, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death 
approaches. J Am Geriatr Soc 2007;55(4): 590-5. 
4. Fahlman C, Lynn J, Finch M, et al. Potentially inappropriate medication use by Medicaid 
Choice beneficiaries in the last year of life. J Palliat Med 2007;10(3): 686-95. 
5. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how 
well can it be measured and optimised? Lancet 2007;370(9582): 173-84. 
6. Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin 
Pharmacol Ther 2009;85(1): 103-7. 
7. O’Mahony D, O’Connor MN. Pharmacotherapy at the end of life. Age Ageing 2011;40:419-
22. 
8. Cruz-Jentoft AJ, Boland B, Rexach L. Drug therapy optimization at the end of life. Drugs 
Aging 2012;29:511-21. 
  
9. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr 
Pharmacother 2007;5(4): 345-51. 
10. Laroche ML, Charmes JP, Bouthier F, et al. Inappropriate medications in the elderly. Clin 
Pharmacol Ther 2008;85(1): 94-7. 
11. Thorpe JM, Thorpe CT, Kennelty KA, et al. The impact of family caregivers on potentially 
inappropriate medication use in non-institutionalized older adults with dementia. Am J Geriatr 
Pharmacother 2012;10(4): 230-41. 
12. Mitchell SL, Kiely DK, Hamel MB. Dying with advanced dementia in the nursing home. 
Arch Intern Med 2004;164(3): 321-6. 
13. McCarthy M, Addington-Hall J, Altmann D. The experience of dying with dementia: a 
retrospective study. Int J Geriatr Psychiatry 1997;12(3):404-9. 
14. Bayer A. Death with dementia-the need for better care. Age Ageing 2006;35(2): 101-2. 
15. Black BS, Finucane T, Baker A, et al. Health problems and correlates of pain in nursing 
home residents with advanced dementia. Alzheimer Dis Assoc Disord 2006;20:283-90. 
16. Shega JW, Hougham GW, Stocking CB, et al. Patients dying with dementia: experience at 
the end of life and impact of hospice care. J Pain Symptom Manage 2008;35:499-507. 
17. Di Giulio P, Toscani F, Villani D, et al. Dying with advanced dementia in long-term care 
geriatric institutions. J Palliat Med 2008;11:1023-8.  
18. Shega J, Tozer C. Improving the care of people with dementia at the end of life: The role 
of hospice and the US experience. Dementia 2009;8(3): 377-89. 
19. Hendriks SA, Smalbrugge M, Hertogh CMPM, et al. Dying with dementia: symptoms, 
treatment, and quality of life in the last week of life. J Pain Symptom Manage 2014;47:710-20. 
  
20. Blass DM, Black BS, Phillips H, et al. Medication use in nursing home residents with 
advanced dementia. Int J Geriatr Psychiatry 2008;23(5):490-6. 
21. Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of 
persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc 
2008;56(7):1306-11. 
22. Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with 
advanced dementia. J Am Geriatr Soc 2010;58;880-8. 
23. Toscani F, Di Giulio P, Villani D, et al. Treatments and prescriptions in advanced 
dementia patients residing in long-term care institutions and at home. J Palliat Med 
2013;16(1);31-7. 
24. Mitchell SL, Kiely DK, Jones RN, et al. Advanced dementia research in the nursing home: 
the CASCADE study. Alzheimer Dis Assoc Disord 2006;20:166-75. 
25. Molist Brunet N, Sevilla-Sánchez D, Amblàs Novellas J, et al. Optimizing drug therapy in 
patients with advanced dementia: a patient-centered approach. Eur Geriatr Med 2014;5:66-71. 
26. Holmes HM, Hayley DC Alexander GC, et al. Reconsidering medication appropriateness 
for patients late in life. Arch Intern Med 2006;166:605-9. 
27. Parsons C, Hughes CM, Passmore AP, et al. Withholding, discontinuing and withdrawing 
medications in dementia patients at the end of life: a neglected problem in the disadvantaged 
dying? Drugs Aging 2010;27(6):435-49. 
28. British National Formulary.Volume 60. London: BMJ Group and Pharmaceutical Press: 
2010. 
29. Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull 1988;24:653-
9. 
  
30. Burns A, Lawlor B, Craig S. Assessment scales in old age psychiatry. 2nd ed. London; 
Martin Dunitz Ltd; 2004. 
31. Powell C. The Delphi technique: myths and realities. J Adv Nurs 2003;41(4),376–82. 
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373-
83. 
33. Pearson Education. SIB-S Manual. Oxford: Pearson Assessment; 2008. 
34. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive 
assessment of psychopathology in dementia. Neurology 1994;44:2308-14. 
35. Lange RT, Hopp GA, Kang N. Psychometric properties and factor structure of the 
Neuropsychiatric Inventory Nursing Home version in an elderly neuropsychiatric population. 
Int J Geriatr Psychiatry 2004;19(5):440-8. 
36. Weiner MF, Martin-Cook K, Svetlik DA, et al. The quality of life in late-stage dementia 
(QUALID) scale. J Am Med Dir Assoc 2000;1(3):114-6. 
37. Kiely DK, Volicer L, Teno J, et al. The validity and reliability of scales for the evaluation 
of end-of-life care in advanced dementia. Alzheimer Dis Assoc Disord 2006;20(3):176-81. 
38. Volicer L, Hurley AC, Blasi ZV. Scales for evaluation of end-of-life care in dementia. 
Alzheimer Dis Assoc Disord 2001;15(4):194–200. 
39. Listone HA, Turoff M. The Delphi Method: Techniques and Applications. Reading, MA: 
Addison-Wesley Publishing Company; 1975. 
40. Campbell SM, Cantrill JA. Consensus methods in prescribing research. J Clin Pharm Ther 
2001;26:5-14. 
  
41. Parsons C, McCorry N, Murphy K, et al. Assessment of factors that influence physician 
decision making regarding medication use in patients with dementia at the end of life. Int J 
Geriatr Psychiatry 2014; 29(3):281-90. 
42. Brown MA, Sampson EL, Jones L, et al. Prognostic indicators of 6-month mortality in 
elderly people with advanced dementia: a systematic review. Palliat Med 2013;7(5):389-400. 
43. Vetrano DL, Tosato M, Colloca G, et al. Polypharmacy in nursing home residents with 
severe cognitive impairment: results from the SHELTER study. Alzheimers Dement 
2013;9:587-93. 
44. Butler DB, Kowall NW, Lawler E, et al. Underuse of diagnostic codes for specific 
dementias in the Veterans Affairs New England healthcare system. J Am Geriatr Soc 2012;60; 
910-5. 
45. Maddison AR, Fisher J, Johnston G Preventive medication use among persons with limited 
life expectancy. Prog Palliat Care 2011;19:15–21. 
46. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy. A new, cost effective 
geriatric - palliative approach for improving drug therapy in disabled elderly people. Israel Med 
Assoc J 2007;9:430-4. 
47. Garfinkel D, Mangin D. Feasibility study of a new systematic approach for discontinuation 
of  multiple medications in older adults: addressing polypharmacy.  Arch Intern Med 
2010;170:1648 -54. 
 
  
  
Table 1. Information collected at baseline and every three months thereafter for up to nine 
months or until death 
Data collected Instrument Source When 
Demographic data  Medical records Baseline 
Type of dementia (if 
available) 
 Medical records Baseline 
Duration of dementia 
and age at diagnosis 
 Medical records Baseline 
Co-morbid medical 
conditions in 
previous 3 months 
Charlson Co-
Morbidity Index [32]  
Medical records Baseline, quarterly 
Medications 
prescribed in 
previous 3 months 
 Medical records Baseline, quarterly, 
death 
Cognitive status FASTa  
SIB-Sb 
Named nurse 
Resident 
Baseline, quarterly 
Baseline, quarterly 
Behavioural status NPI-NHc Named nurse Baseline, quarterly 
Quality of life QUALIDd Named nurse Baseline, quarterly 
Comfort SM-EOLDe 
CAD-EOLDf 
Named nurse 
Named nurse 
Baseline, quarterly 
Within 14 days of 
death 
Cause of death  Medical records Within 14 days of 
death 
aFunctional Assessment (FAST) scale [29, 30] ; a scale with seven major stages, sixteen successive stages and sub-stages.   
bSevere Impairment Battery – Short Version (SIB-S) [33]: This scale comprises 26 scale items in nine cognitive domains (social interaction, 
memory, orientation, language, attention, praxis, visuospatial abilities, constructional abilities, and orientation to name) Scores range fom 0 
to 50. 
cNeuropsychiatric Inventory – Nursing Home version (NPI-NH) [34, 35]. This scale assesses frequency and severity of 12 neuropsychiatric 
symptoms: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, 
nighttime disturbances and appetite/eating change. The total score ranges from 0 to 144. The caregiver distress score is not included in the 
total NPI score . It is generated by summing the occupational disruptiveness scores for each of  the behavioral domains, with total scores 
ranging from 0 to 50. 
dQuality of life in late stage dementia (QUALID) scale; an 11-item scale with a total score ranging from 11 to 55. Lower scores indicate 
higher quality of life. [36] 
e Symptom Management at the End of Life in Dementia (SM-EOLD) [37]. This scale quantifies the frequency with which a resident has 
experienced nine symptoms in the previous three months; pain, shortness of breath, depression, fear, anxiety, agitation, calm, skin 
breakdown, and resistance to care. The score ranges fom 0 to 45, with higher scores indicating better symptom control.  
fComfort Assessment in Dying with Dementia (CAD-EOLD) [38]: this scale assesses 14 symptoms and conditions during the last seven 
days of life (discomfort, pain, restlessness, shortness of breath, choking, gurgling, difficulty in swallowing, fear, anxiety, crying, moaning, 
serenity, peace, and calm). 
  
  
Table 2. Medication appropriateness ratings for nursing home residents with advanced dementia as determined by the Delphi consensus panel 
survey 
Always appropriate Sometimes appropriate Rarely appropriate Never appropriate No consensus reached 
Antiemetics 
Inhaled bronchodilators 
Non-opioid analgesics 
Opioid analgesics 
Lubricating eye drops 
Pressure ulcer products 
Local anaesthetics 
Emollients 
Barrier preparations 
Antidiarrhoeals  
Laxatives 
Antacids 
Proton pump inhibitors  
Histamine-2 receptor 
antagonists 
Antispasmodics and other 
drugs altering gut motility 
Diuretics 
Beta-adrenoreceptor 
blocking drugs  
Nitrates 
Antihistamines  
Mucolytics  
Decongestants 
Cough guppressants  
Hypnotics 
Anxiolytics 
Antipsychotic drugs  
Other antidepressants 
Antiepileptic drugs 
N-methyl-D-aspartate 
receptor antagonists 
Antibacterial drugs 
Antifungal drugs 
Oral antidiabetic drugs 
Thyroid hormones 
Antithyroid drugs 
Anti-arrhythmic drugs 
Alpha-adrenoreceptor 
blocking drugs 
Acetylcholinesterase 
inhibitors 
Mineralocorticoid therapy 
Glucocorticoid therapy 
Calcitonin and parathyroid 
hormone 
Tamsulosin 
Colchicine 
Muscle relaxants 
Parenteral intravenous  
fluids 
Dopaminergic drugs used 
in Parkinson’s disease 
Cytotoxic chemotherapy 
Lipid-regulating drugs 
Central nervous system 
stimulants 
Immunomodulating drugs 
Intravenous nutrition 
Disease modifying 
antirheumatic drugs 
Red blood cell colony 
stimulating factor 
Angiotensin-converting 
enzyme inhibitors and 
angiotensin receptor 
antagonists 
Calcium-channel blockers 
Centrally acting 
antihypertensive drugs 
Vasodilator 
antihypertensive drugs 
Oral anticoagulants 
Parenteral anticoagulants 
Antiplatelet drugs 
(excluding aspirin)  
Aspirin 
Cromoglicate and related 
therapy 
Leukotriene receptor-
antagonists 
Expectorants 
Cardiac glycosides 
Inhaled corticosteroids 
Antimuscarinic drugs used 
in Parkinsonism 
Drugs for management of 
chronic bowel disorders 
Antiviral drugs 
Antiprotozoal drugs and 
anthelmintics 
Insulins 
Other drugs for urinary 
retention 
Electrolytes 
Subcutaneous fluids 
Allopurinol 
  
Non-steroidal anti-
inflammatory drugs 
Anti-infective eye 
preparations 
Corticosteroid and other 
anti-inflammatory eye 
preparations  
Anti-glaucoma eye drops 
Oxygen therapy  
Mouthwashes, gargles and 
dentifrices 
Hyoscine patch 
 
Tricyclic and related 
antidepressant drugs  
Drugs used in vertigo 
Sex hormones 
Antioestrogens 
5α-reductase inhibitors 
Antiandrogens 
Other hormone 
antagonists 
Bisphosphonates 
Drugs for urinary 
frequency, enuresis and 
incontinence 
Iron 
Nutritional supplements 
Enteral nutrition 
Mineral supplements  
Vitamins 
Appetite stimulants 
Rubefacients 
Seasonal influenza 
vaccine 
 
  
Table 3 Nursing home demographics 
NH 
 
Major 
providera 
NH 
category 
Specialised 
dementia 
care 
provided 
No. 
of 
beds 
Location No of 
GP 
surgeries 
No of 
GPs 
Involvement 
of old age 
psychiatry 
team 
1 Yes Private No 40 City 8 14 Yes 
2 No Private Yes            
(9 beds) 
49 Village/ 
rural  
10 20  Yes 
3 No Private No 56 Town 4 21 Yes 
 
aOperator of three or more homes or a publicly listed company 
NH=nursing home; GP=general practice; GPs=general practitioners 
  
 
Table 4 Resident data obtained from interview with the resident's named nurse and cognitive assessment at baseline (BL), three (3), six (6) and nine (9) months 
 
 
Cognitive status measured 
by FASTa 
Scores range from 6E to 7F 
Behavioural status measured by NPI-NHb  
Based on 10 domains.  
Scores range from 12 to 200 
Quality of life measured 
by QUALIDc  
Scores range from 11 to 
55 
Comfort measured by 
SM-EOLDd 
Scores range from 0 to 
45 
Cognitive status 
measured by SIB-Se  
Scores range from 0 to 
50 
Resident 
number 
BL 3m 6m 9m BL Df 3m Df 6m Df 9m Df BL 3m 6m 9m BL 3m 6m 9m BL 3m 6m 9m 
R1.NH1  6e 6e 6e 7a 15 6 15 2 12 4 24 1 30 23 29 25 29 30 27 36     
R2.NH1  7a 7a 7a 7a 4 3 8 6 7 3 9 4 13 20 20 20 24 30 33 29 8    
R3.NH1 6e    31 12       26    21    23    
R4.NH1  7d 7d 7d 7d 10 4 18 4 16 6 29 0 22 24 33 29 33 30 31 31     
R5.NH1  7f    28 6       35    10        
R6.NH2  7a 7a 7a 7a 9 2 16 4 16 2 20 1 13 16 15 15 36 36 40 40 24 16 11 10 
R7.NH2  6e 6e 6e 6e 18 7 19 6 8 0 8 2 14 15 15 14 23 24 28 32 31 35 35 25 
R8.NH2  7a 7a 7a 7a 36 8 44 9 28 6 32 5 38 39 26 30 22 16 15 29 11    
R9.NH2  6e 6e 6e 6e 12 5 16 5 21 6 26 4 11 15 13 21 31 25 24 31 43 31 27 12 
R10.NH2  7d 7d 7d 7d 12 2 12 2 12 1 12 1 18 21 23 26 38 40 40 38     
R11.NH3  7a 7a 7a 7a 10g 5 4 1 4 1 10 2 18 15 22 23 34 40 40 34 24 22 13 8 
R12.NH3  7a 7a   32g 8 14 4     31 19   30 27   45 42   
R13.NH3  7a 7a 7a 7a 1g 1 3 2 8 3 18 1 12 21 18 30 30 21 15 21 40 24 33 34 
R14.NH3  7b 7b 7b  28g 9 24 9 56 18   31 24 25  29 35 22      
R15.NH3  7c    41g 9       48    28        
  
R=Resident 
NH= Nursing Home 
aFunctional Assessment Staging. Ranges from FAST 6E to FAST 7F for recruited residents 
bNPI-NH: Neuropsychiatric Inventory – Nursing Home. Total score ranges from 12 to 120 for the 10 domains summed, with lower scores indicating fewer behavioural symptoms 
cQUALID: Quality of Life in Dementia Scale. Total score ranges from 11 to 55, with lower scores indicating higher quality of life 
dSM-EOLD: Symptom Management at the End of Life in Dementia. Score ranges from 0 to 45, with higher scores indicating better symptom control 
eSIB-S: Severe Impairment Battery – Short Version. Score ranges from 0 to 50, with lower scores indicating greater impairment 
fD: Caregiver distress score. Total score ranges from 0 to 50, with lower scores indicating less occupational disruptiveness 
gChange of nurse completing NPI-NH at 3, 6 and 9 months 
Resident died 
 
No longer resident in nursing home 
 
 
Resident refused/unable to complete 
 
   
Table 5 Number of medications in each appropriateness category and number of residents taking medications in 
these categories at each data collection timepoint 
 
 
Appropriateness category/data 
collection point 
Medications prescribed, n (%) Residents taking medications 
in each category, n (%) 
Baseline   
Never appropriate 61 (25.7) 14 (93.3) 
Rarely appropriate 5 (2.1) 5 (33.3) 
Sometimes appropriate 89 (37.6) 15 (100.0) 
Always appropriate 40 (16.9) 15 (100.0) 
No consensus 5  (2.1) 5 (33.3) 
Not classified 37 (15.6) 13 (86.7) 
Overall 237 (100.0) 15 (100.0) 
3 months   
Never appropriate 53 (23.6) 12 (100.0) 
Rarely appropriate 10 (4.4) 7 (58.3) 
Sometimes appropriate 95 (42.2) 12 (100.0) 
Always appropriate 34 (15.1) 12 (100.0) 
No consensus 2 (0.9) 2 (16.7) 
Not classified 31 (13.8) 11 (73.3) 
Overall 225 (100.0) 12 (100.0) 
6 months   
Never appropriate 43 (22.9) 11 (100.0) 
Rarely appropriate 7 (3.7) 4 (36.4) 
Sometimes appropriate 74 (39.4) 11 (100.0) 
Always appropriate 34 (18.1) 11 (100.0) 
No consensus 5 (2.7) 5 (45.5) 
Not classified 25 (13.3) 10 (90.9) 
Overall 188 (100.0) 11 (100.0) 
9 months   
Never appropriate 39 (24.7) 10 (100.0) 
Rarely appropriate 5 (3.2) 4 (40.0) 
Sometimes appropriate 64 (40.5) 10 (100.0) 
Always appropriate 29 (18.4) 10 (100.0) 
No consensus 2 (1.3) 2 (20.0) 
Not classified 19 (12.0) 8 (80.0) 
Overall 158 (100.0) 10 (100.0) 
Post-death   
Never appropriate 3 (12.0) 1 (25.0) 
Rarely appropriate 1 (4.0) 1 (25.0) 
Sometimes appropriate 11 (44.0) 3 (75.0) 
Always appropriate 7 (28.0) 4 (100.0) 
No consensus 0 (0.0) 0 (0.0) 
Not classified 3 (12.0) 1 (25.0) 
Overall 25 (100.0) 4 (100.0) 
 
